SAVE MONEY ON TRAVEL DEALS

Researchers at the University of Pennsylvania School of Medicine and colleagues at Sangamo BioSciences Inc. of Richmond, Calif., said their goal is to use modified T cells from an HIV-infected person for that person's own treatment. They showed that, by using the zinc fingers, they could reduce the viral load of immune-deficient mice transplanted with engineered T cells.

The researchers, led by Dr. Elena Perez, an assistant professor of pediatrics, and Dr. Carl June, a professor of pathology and laboratory medicine at Penn, are planning a clinical trial in humans in which T cells from HIV patients would have their CCR5 gene -- necessary for the AIDS virus to enter immune system cells -- deliberately knocked out.

The modified T cells could then be infused back into the patients to re-establish their immune system and decrease their viral load.

The research is reported online in the journal Nature Biotechnology.

 BREAKING STORIES

Official: Russia has no melamine victims

N. Korea: Kim Jong Il makes troop visit

Plastic surgery makes advances in wartime

New law puts mental, physical ills on par

Cervical cancer shot gains acceptance

Study: Ginkgo can prevent stroke damage

WHO probes deadly mystery illness

Claim: Magic Johnson 'faked' AIDS

Exercise intervention helps with arthritis

WHO: Mental health stigma unfair

Bird flu survival tied to hands-on therapy

TV star to wed after getting cancer news

NSAIDs linked to lower breast cancer risk

Kids' asthma diagnosis can be a challenge

Herb may help curb bad breath

New procedure to correct sagging breasts

Why pizza may cause women pain, urination

Cocoa powder high in anti-oxidants

Genetic code of malaria parasite sequenced

Cuban exiles irked by aid cutoff rule